Jun 2026 (Q2 FY26) — Aug 7, 2026
Rapid Micro Biosystems Q2 FY26 — Record Consumables and Gross Margin Expansion
Read the full callRapid Micro Biosystems (RPID) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Rapid Micro Biosystems earnings: last reported Fri, 7 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 8.1 | +10.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -153.0 | +14.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -12.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.85 +3.66% · +$0.03
Performance −73.9% 1Y
1Y: $3.26 on 14 Oct 2025 → $0.85. High $4.68 (29 Jan 2026), low $0.82 (14 Oct 2026).
- Previous close
- $0.82
- 52-week range
- $0.82 – $4.68
- One year
- −73.27%
Overview
- Symbol
- RPID
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Rapid Micro Biosystems earnings calls (RPID)
Financials
What the filings say
Net profit, year on year: −9% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 8 | 7 | 7 | 8 | 11 | 8 | 8 |
| Expenses | 20 | 18 | 19 | 19 | 19 | 23 | — | — |
| Operating profit | -12 | -10 | -12 | -12 | -11 | -12 | -14 | -12 |
| Operating margin | −158.3% | −124.5% | −161.8% | −167.3% | −145.1% | −108.2% | −173.1% | −153.0% |
| Other income | 1 | 1 | 0 | 0 | -0 | -0 | -0 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Net profit | -11 | -10 | -11 | -12 | -12 | -12 | -14 | -13 |
| EPS ($ per share) | -0.26 | — | -0.26 | -0.27 | -0.26 | — | -0.31 | -0.27 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Reserves | -242 | -315 | -376 | -428 | -475 | -522 |
| Total liabilities | 45 | 20 | 26 | 25 | 23 | 42 |
| Fixed assets | 7 | 11 | 14 | 13 | 11 | 9 |
| Investments | 15 | 15 | — | — | — | — |
| Total assets | 70 | 241 | 191 | 143 | 98 | 75 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -31 | -55 | -59 | -45 | -44 | -31 |
| Cash from investing | -16 | -13 | -93 | 42 | 37 | 14 |
| Cash from financing | 64 | 217 | 1 | 0 | 0 | 20 |
| Capital expenditure | -1 | -3 | -7 | -2 | -1 | -1 |
| Free cash flow | -32 | -58 | -65 | -47 | -46 | -32 |
Insider filings
37 filings between Oct 17, 2025 and Jul 24, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.14M
14 sales by 4 insiders
Compensation
not trading decisions- 13
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift, 1 option exercised.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Longitude Capital Partners II, LLC | — | $663.9K | Feb 4, 2026 |
| Spignesi Robert G. Jr. | — | $271.2K | Mar 10, 2026 |
| WIRTJES SEAN M | — | $122.8K | Mar 11, 2026 |
| Wilson John J. Addington | — | $80.1K | Mar 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 24, 2026 | Kollender Richard S Director | Option exercise | 1,827 | $1.4K |
| Jul 24, 2026 | Kollender Richard S Director | Option exercise | 1,681 | $1.3K |
| Jul 22, 2026 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 1,402 | $1.1K |
| May 29, 2026 | WIRTJES SEAN M CHIEF FINANCIAL OFFICER | Award | 12,787 | $25.0K |
| May 29, 2026 | Malloy Kirk Director | Award | 12,787 | $25.0K |
| May 29, 2026 | PEI MELINDA LITHERLAND Director | Award | 12,787 | $25.0K |
| May 29, 2026 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Award | 12,787 | $25.0K |
| May 29, 2026 | LOWENSTEIN INESE Director | Award | 12,787 | $25.0K |
| May 21, 2026 | Malloy Kirk Director | Award | 19,300 | $0 |
| May 21, 2026 | Kollender Richard S Director | Award | 19,300 | $0 |
| May 21, 2026 | PEI MELINDA LITHERLAND Director | Award | 19,300 | $0 |
| May 21, 2026 | LOWENSTEIN INESE Director | Award | 19,300 | $0 |
| May 21, 2026 | Bika Dafni Director | Award | 19,300 | $0 |
| Mar 11, 2026 | WIRTJES SEAN M CHIEF FINANCIAL OFFICER | Sale | 7,480 | $32.3K |
| Mar 11, 2026 | Wilson John J. Addington CHIEF OPERATING OFFICER | Sale | 9,603 | $41.5K |
| Mar 10, 2026 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 17,922 | $73.7K |
| Feb 27, 2026 | RICCIARDI NATALE S Director | Option exercise | 842 | $632 |
| Feb 20, 2026 | WIRTJES SEAN M CHIEF FINANCIAL OFFICER | Sale | 17,254 | $67.7K |
| Feb 20, 2026 | Wilson John J. Addington CHIEF OPERATING OFFICER | Sale | 5,403 | $21.2K |
| Feb 19, 2026 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 38,327 | $148.9K |
| Feb 11, 2026 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Award | 264,000 | $0 |
| Feb 11, 2026 | WIRTJES SEAN M CHIEF FINANCIAL OFFICER | Award | 97,000 | $0 |
| Feb 11, 2026 | Wilson John J. Addington CHIEF OPERATING OFFICER | Award | 74,000 | $0 |
| Feb 9, 2026 | Wilson John J. Addington CHIEF OPERATING OFFICER | Sale | 4,610 | $17.4K |
| Feb 9, 2026 | WIRTJES SEAN M CHIEF FINANCIAL OFFICER | Sale | 6,027 | $22.8K |
| Feb 9, 2026 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 12,840 | $48.6K |
| Feb 4, 2026 | Longitude Capital Partners II, LLC 10% owner | Sale | 49,000 | $190.1K |
| Feb 3, 2026 | Longitude Capital Partners II, LLC 10% owner | Sale | 27,500 | $116.6K |
| Feb 2, 2026 | Longitude Capital Partners II, LLC 10% owner | Sale | 27,500 | $116.8K |
| Jan 30, 2026 | Longitude Capital Partners II, LLC 10% owner | Sale | 46,000 | $209.0K |
| Jan 23, 2026 | Longitude Capital Partners II, LLC 10% owner | Sale | 7,739 | $31.5K |
| Jan 23, 2026 | Longitude Capital Partners II, LLC 10% owner | Option exercised | 629,032 | $31.5K |
| Nov 14, 2025 | Malloy Kirk Director | Gift | 40,000 | $0 |
| Oct 17, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Tax withheld | 2,072 | $6.4K |
| Oct 17, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 3,400 | $2.5K |
| Oct 17, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 7,833 | $5.9K |
| Oct 17, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Tax withheld | 4,774 | $14.7K |
| Jul 14, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 25,145 | $0 |
| Jul 14, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 11,881 | $39.5K |
| Jul 11, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 11,874 | $39.5K |
| Jul 11, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 25,145 | $0 |
| Jul 10, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 11,617 | $39.5K |
| Jul 10, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 25,145 | $0 |
| Jul 9, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 11,247 | $39.5K |
| Jul 9, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 25,144 | $0 |
| Jul 8, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Sale | 10,824 | $38.0K |
| Jul 8, 2025 | Spignesi Robert G. Jr. PRESIDENT AND CEO | Option exercise | 25,144 | $0 |
| May 22, 2025 | RICCIARDI NATALE S Director | Award | 14,300 | $0 |
| May 22, 2025 | Malloy Kirk Director | Award | 14,300 | $0 |
| May 22, 2025 | Kollender Richard S Director | Award | 14,300 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for RAPID MICRO BIOSYSTEMS, INC.
Free account. Everything above stays public.
Write why you follow RAPID MICRO BIOSYSTEMS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading